Broadcast Date: February 9, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

The number of targeted therapies and the complexity of biomarker detection linked to these therapies has grown over the last decade. To accommodate it, the drug development process must also evolve. In this Clinical OMICs webinar, we will discover how combining molecular and immune profiling’s power to drive molecular-based testing is improving stratification methods and patient outcomes. Additionally, our expert panelist will showcase the impact of a scalable, comprehensive assay, and infrastructure in the context of drug development.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Produced with support from:

illumina logo
Jeffrey ConroyJeffrey Conroy
Chief Scientific Officer, OmniSeq
Director, Roswell Park Comprehensive
Cancer Center
Also of Interest